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Introduction
Most smokers report a desire and intention to quit, but while 
nearly half attempt to quit in any given year, only 2%–3% actu-
ally succeed (Twigg, Moon, Szatkowski, & Iggulden, 2009). The 
majority of quit attempts fail within days (Hughes, 2003), even 
with treatment, so that better treatment strategies are needed. 
Smoking behaviors, including heaviness of smoking and smok-
ing cessation, are known to be under a degree of genetic influ-
ence (Munafo, Clark, Johnstone, Murphy, & Walton, 2004), 
and  elucidating  the  genetic  predictors  of  smoking  behaviors 
may help to develop new pharmacotherapies for smoking cessa-
tion or identify subgroups for whom more intensive support 
may be necessary.
The enzyme catechol O-methyltransferase (COMT) is of 
relevance in studies of smoking behavior and smoking cessation 
due to its presence in dopaminergic brain regions. Its role is to 
degrade  and  inactivate  neuronally  released  dopamine  (Akil 
et al., 2003; Chen et al., 2004). The Val108/158Met polymorphism 
(rs4680) is located in exon 3 of the COMT gene and is a G > A 
(G1947A) transition that results in the substitution of a valine 
(G; Val) by a methionine (A; Met; Jonsson et al., 1999) at codon 
108/158 for S-COMT/MB-COMT, respectively (Lachman et al., 
1996). The A (Met) allele results in a threefold to fourfold re-
duction in COMT enzyme activity, which is  hypothesized to 
result in relatively greater dopamine activity (Shield, Thomae, 
Eckloff, Wieben, & Weinshilboum, 2004). The chromosomal 
region (22q12) on which COMT is located has shown linkage 
with heavy smoking behavior (Saccone et al., 2007), and a num-
ber of studies have investigated the association between COMT 
rs4680 genotype and smoking behavior. Two studies have re-
ported higher tobacco dependence among individuals carrying 
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the A (Met) allele (Beuten, Payne, Ma, & Li, 2006; Guo et al., 
2007), while another has reported an association between the A 
(Met) allele and increased smoking following exposure to an 
acute stressor (Amstadter et al., 2009). However, one study has 
reported a higher frequency of the G (Val) allele among smokers 
compared with nonsmokers (Nedic et al., 2010), while another 
has reported an association of the G (Val) allele with persistent 
smoking among light smokers (Shiels et al., 2008). Finally, one 
study failed to observe an association between COMT rs4680 
genotype and heaviness of smoking (McKinney et al., 2000).
We recently reported evidence for a moderating effect of 
COMT rs4680 genotype on the relative efficacy of nicotine replace-
ment therapy (NRT) transdermal patch compared with placebo 
(Johnstone et al., 2007). NRT produced relatively greater benefit 
compared with placebo in producing abstinence in individuals 
with the COMT AA (Met/Met) genotype compared with those 
with either the AG (Met/Val) or the GG (Val/Val) genotype. We 
subsequently replicated this association of the A (Met) allele with 
improved response to NRT in an open-label trial of the NRT trans-
dermal patch (Munafo, Johnstone, Guo, Murphy, & Aveyard, 
2008). Other studies have also investigated the role of the COMT 
gene in response to smoking cessation pharmacotherapy. Colilla 
et al. (2005) found that women who were homozygous for the 
low-activity A (Met) allele were more likely than those with the 
high-activity G (Val) allele to be abstinent from smoking at the end 
of a period of NRT, while Berrettini et al. (2007) found that a 
COMT haplotype of two single-nucleotide polymorphisms 
(including Val108/158Met) was associated with greater likelihood 
of abstinence in individuals treated with bupropion. However, 
Ton et al. (2007) reported no association of COMT genotype 
with cessation in almost 600 women taking part in a trial of 
d,l-fenfluramine for smoking cessation. Two recent investiga-
tions have shown an association between COMT genotype and 
smoking behavior in women only (Beuten et al., 2006; Colilla 
et al., 2005), although we did not observe sex differences in 
the association of COMT genotype with response to  NRT 
(Johnstone et al., 2007).
However, Omidvar et al. (2009) reported data from more than 
5,000 individuals indicating that, in elderly smokers, a reduced like-
lihood of cessation is associated with A (Met) allele carriers, while 
Breitling et al. (2009) did not observe an association between the 
COMT rs4680 polymorphism and cessation in a cohort of more 
than 1,400 heavy smokers, of whom more than 900 achieved absti-
nence, and David et al. (2002) did not observe an association with 
smoking status in more than 500 current smokers and ex-smokers. 
It is notable that in all these studies, smokers were drawn from 
community-based samples and were not explicitly recruited to be 
treatment seeking, unlike the studies of smokers participating in 
clinical trials described above. Given that the majority of cessation 
attempts do not include the use of behavioral support of pharma-
cotherapy (Chapman & MacKenzie, 2010), it is likely that most 
cessation attempts in these community-based smokers were 
spontaneous and unassisted.
An endemic difficulty in the search for genetic variants 
associated with complex behavioral phenotypes is the lack of 
robust  replication  (Colhoun,  McKeigue,  &  Davey  Smith, 
2003; Ioannidis, Ntzani, Trikalinos, & Contopoulos-Ioannidis, 
2001): Initially promising findings are frequently followed by 
failures to replicate or opposite findings. Consistent with this 
pattern, while COMT has emerged as one of the more prom-
ising candidate genes for smoking behavior, some inconsis-
tencies  have  begun  to  emerge.  Clearly,  further  research, 
ideally in large prospective cohorts, is needed to investigate 
whether COMT rs4680 genotype predicts smoking behavior. 
We therefore explored whether the COMT rs4680 A (Met) allele 
predicts increased heaviness of smoking and persistent smoking 
during pregnancy in a large population-based cohort of preg-
nant women, given the considerable proportion of women who 
stop smoking during pregnancy (Munafo, Heron, & Araya, 
2008) due to the health and social pressures to do so.
Methods
Participants
We studied pregnant women of European ancestry from the 
Avon Longitudinal Study of Parents and Children (ALSPAC; 
Golding, Pembrey, & Jones, 2001), a prospective study that re-
cruited pregnant women from Bristol, UK, with expected deliv-
ery dates between April 1991 and December 1992. All women 
gave informed consent, and ethical approval for the study was 
obtained from the ALSPAC Law and Ethics Committee and the 
Local Research Ethics Committees.
Data Collection
Cigarette smoking behavior of women before and during preg-
nancy was determined from questionnaires. A questionnaire was 
administered in the 18th gestational week asking about lifetime, 
prepregnancy, and first-trimester smoking behavior (whether or 
not the woman smoked and, for smokers, the quantity of ciga-
rettes per day) and another in the 32nd week asking about current 
smoking behavior. At each timepoint, the data on smoking quan-
tity were categorized into 1–9, 10–19, and 20+ cigarettes/day. 
Data on known covariates of smoking behavior (Lu, Tong, & 
Oldenburg, 2001) were also collected via questionnaire, including 
age, age started smoking, socioeconomic position (Szreter, 1984), 
educational level, parity, and partner’s smoking status.
Genotyping
The COMT rs4680 polymorphism was genotyped in participants 
using standard methods. Genotyping was performed by KBio-
sciences (Hoddesdon, UK; www.kbioscience.co.uk), using their 
own  system  of  fluorescence-based  competitive  allele-specific 
polymerase chain reaction (KASPar). The genotyping call rate 
was >95%. The percentage of duplicate samples included for 
genotyping was 9%. Concordance between duplicate samples 
was >99%. There was no evidence of deviation from Hardy–
Weinberg equilibrium (p = .43).
Statistical Methods
We selected women of European ancestry on whom data on 
COMT  rs4680  genotype  and  cigarette  smoking  immediately 
prior  to  pregnancy  were  available.  We  assumed  an  additive 
model of genetic action based on prior evidence that the rs4680 
polymorphism  is  codominant  (Weinshilboum,  Otterness,  & 
Szumlanski, 1999). This, combined with the roughly equal allele 
frequencies, increases the statistical power of this approach.
First, we assessed the association between the prepreg-
nancy, first trimester and third trimester smoking quantity 57
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(cigarettes  per  day),  and  the  rs4680  polymorphism  by 
performing  linear  regression  of  smoking  quantity  level  on 
number of A (Met) alleles. We also dichotomized smoking 
quantity to reflect “light” (1–9 cigarettes/day) and “heavy” 
(10+ cigarettes/day) smoking. We assessed the association be-
tween this variable and the number of A (Met) alleles using 
logistic  regression.  We  repeated  these  analyses  including 
known covariates of smoking behavior (age, age started smok-
ing,  socioeconomic  position,  educational  level,  parity,  and 
partner’s smoking status).
Second,  we  assessed  the  association  between  persistent 
smoking in the first trimester and third trimester and the rs4680 
polymorphism. Participants were classified, using data collected 
on first trimester smoking, as “stopped smoking” or “continued 
to smoke.” A similar dichotomous variable was created using 
data on third trimester smoking assessed at 32 weeks. We per-
formed logistic regression to assess the association between each 
dichotomized variable and number of A (Met) alleles. We re-
peated these analyses including known covariates of behavior 
and heaviness of smoking prior to pregnancy.
We also used bootstrapping methods to derive the regres-
sion error for the logistic regression models nonparametrically. 
For each model, we drew 10,000 samples with replacement   
using the R boot library (www.r-project.org) in order to create 
a  sampling  distribution  of  the  statistic  of  interest.  Boot-
strapped regression estimates, their errors, and 95% CIs (cor-
responding to the 2.5th and 97.5th percentiles) were derived 
on  the  logit  scale  and  subsequently  transformed  into  odds 
ratios (ORs). Bootstrap p values (pempirical) were based on Wald 
tests.
Third, given the risk of chance findings in genetic associa-
tion studies and in an attempt to resolve the discrepancy be-
tween studies of the COMT rs4680 polymorphism and both 
heaviness of smoking (light vs. heavy smokers, as defined above) 
and persistent smoking (current smokers vs. ex-smokers), we 
combined our data with those from previous studies in com-
munity samples (Breitling et al., 2009; David et al., 2002; Guo et 
al., 2007; Omidvar et al., 2009; Shiels et al., 2008). We used our 
prepregnancy heaviness of smoking and first trimester persis-
tent smoking data as described above. Data were initially ana-
lyzed  within  a  fixed  effects  framework  and  individual  study 
allelic ORs pooled using inverse variance methods to generate a 
pooled OR and 95% CI. A fixed effects framework assumes that 
the association between genotype and phenotype is constant 
across studies, and between-study variation is considered to be 
due  to  chance  or  random  variation.  This  assumption  was 
checked using a c2 test of goodness of fit for homogeneity. The 
p value of the pooled OR was determined using a Z test and the 
percentage of total variation across studies due to heterogeneity 
quantified using the I2 statistic. Conventionally, values of 25%, 
50%, and 75% represent low, moderate, and high heterogeneity, 
respectively  (Higgins,  Thompson,  Deeks,  &  Altman,  2003). 
Where  there  was  evidence  of  association  in  the  presence  of 
moderate to high between-study heterogeneity, a random ef-
fects framework was employed, with ORs pooled using DerSi-
monian  and  Laird  methods.  A  random  effects  framework 
assumes that between-study variation is due to both chance or 
random variation and an individual study effect. Random ef-
fects models are more conservative than fixed effects models 
and generate a wider CI. We tested for small study bias, such as 
may arise from publication bias, using Egger’s test (Egger, Davey 
Smith, Schneider, & Minder, 1997).
Results
Characteristics of Participants
There were n = 6,227 pregnant women of European ancestry 
on whom data on COMT rs4680 genotype and smoking sta-
tus immediately prior to pregnancy were available. A total of 
n  =  2,001  women  reported  smoking  immediately  prior  to 
pregnancy, of whom n = 547 reported not smoking in the first 
trimester and n = 849 reported not smoking in the third tri-
mester. Basic sample characteristics are presented in Table 1.
Using data on all participants, the A (Met) allele was associ-
ated with smoking status prior to pregnancy (OR = 1.11, 95% 
CI = 1.03–1.20, p = .007), with the A (Met) allele more common 
Table 1. Characteristics of Participants
All women  
(n = 6,227),
n (%)
Smokers 
(n = 2,001), 
n (%)
Quit 18 week  
(n = 547), 
n (%)
Quit 22 week  
(n = 849),
 n (%)
Age (years)
  <20 209 (3) 143 (7) 29 (5) 63 (7)
  20–29 3,582 (58) 1,285 (64) 340 (62) 535 (63)
  >30 2,436 (39) 573 (29) 178 (33) 251 (30)
Age started smoking (years)
  <16 n/a 746 (38) 156 (29) 275 (33)
  16–19 n/a 1048 (53) 304 (56) 457 (54)
  20+ n/a 186 (9) 80 (15) 110 (13)
Socioeconomic statusa
  I/II 1,905 (35) 442 (26) 146 (30) 218 (30)
  III 2,935 (54) 938 (56) 265 (55) 405 (55)
  IV/V 624 (11) 293 (18) 70 (15) 114 (15)
Educational levelb
  CSE/ 
    vocational
1,786 (29) 832 (42) 174 (32) 296 (35)
  O-level 2,217 (36) 704 (35) 206 (38) 300 (35)
  A-level/ 
    degree
2,199 (35) 457 (23) 166 (30) 251 (30)
Parityc
  0 2,827 (46) 986 (50) 318 (59) 509 (61)
  1 2,168 (35) 593 (30) 149 (28) 207 (25)
  2+ 1,160 (19) 389 (20) 70 (13) 120 (14)
Partner smoking
  Yes 2,168 (36) 1,165 (62) 267 (50) 422 (52)
  No 3,839 (64) 719 (38) 263 (50) 385 (48)
Note. A-level = Advanced Level; CSE = Certificate of Secondary 
Education; n/a = not applicable; O-level = Ordinary Level.
aData on socioeconomic status based upon the Registrar General’s 
1980 (Szreter, 1984) classification (I, II, III Non-Manual, III Manual, IV, 
and V, where I represents professional and V unskilled manual).
bEducational data ranked according to level of attainment (lowest: 
CSE/vocational and highest: A-level/degree), with O-level qualifications 
typically taken at 16 years and A-level qualifications typically taken at 
18 years.
cParity indicates the number of times the participant had given birth.58
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among  smokers  than  among  nonsmokers.  However,  when 
known covariates of smoking behavior were included, no asso-
ciation was observed (OR = 1.03, 95% CI = 0.91–1.17, p = .65). 
The association of COMT rs4680 genotype with these covariates 
is presented in Table 2.
Table 2. COMT rs4680 Genotype and 
Covariates of Smoking Behavior
GG  
(Val/Val)
GA  
(Val/Met)
AA  
(Met/Met) p valuea
Age (years)
  <20 39 (19) 106 (51) 64 (30) .083
  20–29 831 (23) 1,779 (50) 972 (27)
  >30 590 (24) 1,207 (50) 639 (26)
Age started smoking (years)
  <16 213 (20) 533 (51) 309 (29) .255
  16–19 386 (23) 847 (50) 447 (27)
  20+ 67 (22) 148 (48) 91 (30)
Socioeconomic statusb
  I/II 461 (24) 957 (50) 487 (26) .026
  III 704 (24) 1,451 (49) 780 (27)
  IV/V 132 (21) 298 (48) 194 (31)
Educational levelc
  CSE/vocational 389 (22) 888 (50) 509 (28) .010
  O-level 518 (23) 1,106 (50) 593 (27)
  A-level/degree 546 (25) 1,087 (49) 566 (26)
Parityd
  0 684 (24) 1,384 (49) 759 (26) .812
  1 472 (22) 1,107 (51) 589 (27)
  2+ 284 (24) 566 (49) 310 (27)
Partner smoking
  Yes 474 (22) 1,070 (49) 624 (29) .003
  No 943 (25) 1,902 (49) 994 (26)
Note. Analyses restricted to pregnant women of European ancestry on 
whom data on smoking status immediately prior to pregnancy were 
available (n = 6,227).
aLinear association chi-square test.
bData on socioeconomic status based upon the Registrar General’s 
1980 (Szreter, 1984) classification (I, II, III Non-Manual, III Manual, IV, 
and V, where I represents professional and V unskilled manual).
cEducational data ranked according to level of attainment (lowest: 
CSE/vocational and highest: A-level/degree), with O-level qualifications 
typically taken at 16 years and A-level qualifications typically taken at 
18 years.
dParity indicates the number of times the participant had given birth.
Table 3. COMT rs4680 Genotype and Heaviness of Smoking
Prepregnancy First trimester Third trimester
Logistic regression
  Unadjusted OR (95% CI) 1.23 (1.06–1.42) 1.24 (1.09–1.41) 1.16 (0.98–1.38)
  Adjusted OR (95% CI) 1.20 (1.02–1.42) 1.23 (1.06–1.43) 1.08 (0.88–1.32)
Linear regression
  Unadjusted B (95% CI) +0.05 (+0.00 to +0.10) +0.07 (+0.02 to +0.13) +0.07 (+0.01 to +0.13)
  Adjusted B (95% CI) +0.05 (−0.00 to +0.11) +0.06 (+0.00 to +0.12) +0.04 (−0.03 to+0.11)
Note. Adjusted estimates include correction for age, age started smoking, socioeconomic status, educational level, parity, and partner smoking. 
OR = odds ratio.
Heaviness of Smoking
Among smokers on whom heaviness of smoking data were avail-
able (n = 1,132–1,963), logistic regression analyses indicated that 
the A (Met) allele was associated with increased heaviness of smok-
ing (dichotomized as 1–9 cigarettes/day vs. 10+ cigarettes/day) be-
fore pregnancy (OR = 1.23, 95% CI = 1.06–1.42, p = .005, pempirical = 
.004), during the first trimester (OR = 1.24, 95% CI = 1.09–1.41, 
p = .001, pempirical = .001), with marginal evidence of association dur-
ing the third trimester (OR = 1.16, 95% CI = 0.98–1.38, p = .080, 
pempirical = .081), most likely due to reduced numbers of smokers and 
lower power during this period. Linear regression analyses pro-
duced similar findings. When known covariates of smoking behav-
ior were included, these results were not altered substantially. These 
results are presented in Table 3.
Persistent Smoking in Pregnancy
Among  those  who  reported  smoking  prior  to  pregnancy  on 
whom  smoking  status  data  during  pregnancy  were  available   
(n = 1,998), we did not observe an association between the 
A (Met) allele and the odds of continuing to smoke in pregnancy 
either in the first trimester (OR = 1.07, 95% CI = 0.93–1.23, 
p = .37, pempirical = .37) or in the third trimester (OR = 0.97, 95% 
CI = 0.86–1.11, p = .67, pempirical = .68). When known covariates 
of smoking behavior and heaviness of smoking prior to preg-
nancy were included, these results were not altered substantially. 
These results are presented in Table 4.
Meta-Analysis
Meta-analysis of individual study allelic ORs, within a fixed ef-
fects framework (Munafo & Flint, 2004), indicated some evi-
dence  of  association  of  the  A  (Met)  allele  with  increased 
heaviness of smoking (k = 14, n = 13,312, OR = 1.07, 95% CI = 
1.01–1.13, p = .035). There was low between-study heterogene-
ity (I2 = 17%, c2 [13] = 15.60, p = .27). These results are pre-
sented  in  Figure  1  and  were  not  altered  substantially  when 
dominant and recessive models of genetic action were tested. 
Egger’s test did not indicate any evidence of small study bias,  
t(12) = 0.54, p = .60.
A similar meta-analysis of individual study allelic ORs did 
not indicate any evidence of association of the A (Met) allele 
with persistent smoking (k = 7, n = 11,469, OR = 1.03, 95% 
CI = 0.97–1.09, p = .34). There was no between-study heteroge-
neity (I2 = 0%, c2 [6] = 4.41, p = .64). These results are pre-
sented in Figure 2 and were not altered substantially when we 
used our data on third trimester smoking status or when domi-
nant and recessive models of genetic action were tested. Egger’s 59
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Table 4. COMT rs4680 Genotype and 
Smoking Cessation
GG (Val/Val) GA (Val/Met) AA (Met/Met)
First trimester
  Smoking, n (%) 295 (70) 746 (73) 410 (73)
  Quit, n (%) 126 (30) 269 (27) 152 (27)
Third trimester
  Smoking, n (%) 244 (58) 587 (58) 318 (57)
  Quit, n (%) 177 (42) 429 (42) 243 (43)
Note. Analyses restricted to women who reported smoking cigarettes 
immediately prior to pregnancy (n = 2,001).
test did not indicate any evidence of small study bias, t(12) = 
0.14, p = .90.
Power Analysis
The results of our meta-analysis indicated that, in order to de-
tect any effect of COMT rs4680 on persistent smoking or heavi-
ness of smoking, a primary sample in excess of n = 25,000 
would  be  required  to  achieve  80%  power  at  an  alpha  level   
of .05. Therefore, although we detected evidence of association 
in our primary sample, further replication in a larger sample 
would  be  desirable.  Power  analyses  were  conducted  using 
G*Power  3.1  (Faul,  Erdfelder,  Lang,  &  Buchner,  2007)  and 
assumed a minor G (Val) allele frequency of 47% consistent 
with our meta-analysis.
Discussion
Our data suggest a weak association between COMT genotype 
and heaviness of smoking, which survived correction for age, 
age started smoking, socioeconomic position, educational level, 
parity, and partner’s smoking status. This finding is supported 
by our meta-analysis, which indicated a small effect equivalent 
to <1% phenotypic variance, consistent with the growing con-
sensus that single gene effects on complex phenotypes are likely 
to  be  very  small  (Clarke,  Flint,  Attwood,  &  Munafo,  2010). 
However, it should be noted that the strength of evidence for 
this association was modest, and the observed effect size was   
reduced in our meta-analysis compared with our primary sam-
ple. Furthermore, these effects did not reach genomewide sig-
nificance  and  would  not  survive  correction  for  multiple 
comparisons based on the two primary phenotypes we investi-
gated. Therefore, COMT remains a plausible candidate gene for 
smoking behavior phenotypes, in particular, heaviness of smok-
ing (and, by extension, tobacco dependence), but any effect is 
likely to be small, and further research is necessary to establish 
conclusively whether it is genuine.
Neither our primary data nor our meta-analysis support an 
association  between  COMT  genotype  and  the  likelihood  of 
stopping smoking, which is at odds with previous reports of an 
association with smoking cessation among treatment-seeking 
smokers  (Johnstone  et  al.,  2007;  Munafo,  Johnstone,  et  al., 
2008). One possibility suggested by these data is that the effects 
of COMT on smoking cessation may differ as a function of 
whether the cessation attempt is aided or unaided and, in par-
ticular, whether NRTs are used, given evidence of a moderating 
effect of COMT on response to NRT (Johnstone et al., 2007; 
Munafo, Johnstone, et al., 2008). A difficulty with existing data 
from clinical trials is that these tend to be smaller than those 
from community-based studies, so that while it is possible that 
effects of COMT differ between these populations (possibly as a 
function of medication use), it is also possible that the differ-
ence is due to the higher risk of false positives in smaller sam-
ples. This possibility will need to be explored in future studies of 
treatment-seeking smokers.
Converging evidence for a role of COMT in smoking behavior 
comes from neuroimaging studies. Brody et al. (2006) reported 
that COMT genotype moderated the effect of cigarette smoking 
on dopamine (DA) release, with the Val (G) allele associated 
with greater DA release following smoking. COMT is of particu-
lar interest given the relatively prominent role of the COMT 
enzyme in DA degradation in the prefrontal cortex, given the 
relative lack of dopamine transporters in this region. However, 
functionally, the Met (A) allele also appears to result in in-
creased levels of tonic DA and reciprocal reductions in phasic 
DA released in subcortical regions (Bilder, Volavka, Lachman, & 
Grace,  2004).  Therefore,  Val  (G)  allele  carriers  with  higher 
COMT enzyme activity may have decreased tonic intrasynaptic 
Figure 1.  Meta-analysis of COMT rs4680 genotype and heaviness of smoking. Fixed effects meta-analysis of COMT rs4680 genotype and heavi-
ness of smoking indicates some evidence of association of the A (Met) allele with increased heaviness of smoking (bottom row). Data from the 
primary sample in the current study are included as present study.60
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Figure 2.  Meta-analysis of COMT rs4680 genotype and persistent smoking. Fixed effects meta-analysis of COMT rs4680 genotype and persistent 
smoking indicates no evidence of association of the A (Met) allele with persistent smoking (bottom row). Data from the primary sample in the 
current study are included as Munafo (2010).
DA levels, leading to increased smoking-induced phasic DA re-
lease (Brody et al., 2006). A recent review (Contin et al., 2004) 
supports this possibility by suggesting that Val (G) allele carriers 
may have lower tonic extraneuronal DA and higher phasic DA 
subcortically compared with Met (A) allele carriers. As a result, 
Met (A) allele carriers may smoke more heavily in order to ob-
tain equivalent levels of phasic DA release.
There are some limitations to our study that should be consid-
ered when interpreting these results. First, smoking status in the 
ALSPAC sample was not biochemically verified. However, this is 
offset by the relatively large sample size and prospective nature of 
data collection. In addition, there are no reasons to believe that 
misreporting would differ by genotype, so the likelihood of sys-
tematic bias is low. Second, COMT genotype was associated with 
socioeconomic position and educational attainment in our sam-
ple. There is no reason to believe that this reflects anything other 
than a chance finding, given the extensive evidence that in general, 
genetic variants are not related to such factors (Davey-Smith et al., 
2007)—and particularly because this association is in the opposite 
direction to that which has been reported for general intelligence 
(Barnett, Scoriels, & Munafo, 2008). However, we adjusted our 
analyses for covariates related to smoking behavior, including so-
cioeconomic position and educational attainment, and our find-
ings with respect to heaviness of smoking were robust to these 
adjustments. Third, we did not collect data on concurrent medica-
tion use in our sample and, in particular, whether participants 
were using any smoking cessation pharmacotherapies to assist 
them in stopping. However, at the time of data collection, only 
nicotine replacement products were available for smoking cessa-
tion in the United Kingdom, and these were not available over the 
counter and not licensed for prescription to pregnant women. In 
addition, bupropion is not licensed as an antidepressant in the 
United Kingdom. It is therefore highly unlikely that many (if any) 
of the participants in our sample were using medications with ef-
fects on smoking cessation or heaviness of smoking. Fourth, asso-
ciation between the rs4680 variant and smoking behavior has not 
been reported in recent large genomewide association (GWA) 
studies of smoking phenotypes, including heaviness of smoking 
(Liu et al., 2010; Thorgeirsson et al., 2010; Tobacco-and-Genetics-
Consortium, 2010), despite the variant being included on relevant 
GWA arrays. One possible reason is that the effect of the rs4680 
variant is too small to appear among the top hits followed up in 
these studies. Another possibility is simply that our results repre-
sent a chance finding, given the small observed effect size and rela-
tively  modest  sample  available  for  analysis,  even  in  our 
meta-analysis. This is a particular problem, given the history of 
nonreplication in genetic association studies (Davey-Smith et al., 
2007; Munafo, 2009), and therefore, further replication in a larger 
independent sample would be desirable.
In conclusion, our data suggest weak evidence of association 
of the COMT rs4680 polymorphism with heaviness of smoking 
but not smoking cessation or persistent smoking. While the re-
sults of our meta-analysis did not indicate substantial between-
study heterogeneity or the presence of small study bias, the lack 
of convergent evidence from recent GWA studies somewhat un-
dermines confidence in these results. Nevertheless, COMT ap-
pears  to  remain  a  candidate  gene  for  smoking  behavior, 
warranting further investigation.
Funding
The UK Medical Research Council (74882), the Wellcome Trust 
(076467), and the University of Bristol provide core support for 
ALSPAC. This research was specifically funded by the Wellcome 
Trust (086684). RMF is funded by a Sir Henry Wellcome Post-
doctoral Fellowship (085541). GDS works in a centre (CAiTE) 
that  is  supported  by  the  UK  Medical  Research  Council 
(G0600705) and the University of Bristol.61
Nicotine & Tobacco Research, Volume 13, Number 2 (February 2011) 
Declaration of Interests
None declared.
Acknowledgments
We are extremely grateful to all the families who took part in 
this  study,  the  midwives  for  their  help  in  recruiting  them,   
and the whole ALSPAC team, which includes interviewers, 
computer  and  laboratory  technicians,  clerical  workers,  re-
search  scientists,  volunteers,  managers,  receptionists,  and 
nurses. We are also grateful to the study authors who released 
their data in a format  that enabled their inclusion in our 
meta-analysis. This publication is the work of the authors, and 
Marcus Munafò will serve as guarantor for the contents of this 
paper.
References
Akil,  M.,  Kolachana,  B.  S.,  Rothmond,  D.  A.,  Hyde,  T.  M., 
Weinberger,  D.  R.,  &  Kleinman,  J.  E.  (2003).  Catechol-O- 
methyltransferase  genotype  and  dopamine  regulation  in  the   
human brain. Journal of Neuroscience, 23, 2008–2013. Retrieved 
from http://www.jneurosci.org/
Amstadter, A. B., Nugent, N. R., Koenen, K. C., Ruggiero, K. J., 
Acierno, R., Galea, S., et al. (2009). Association between COMT, 
PTSD, and increased smoking following hurricane exposure in 
an epidemiologic sample. Psychiatry, 72, 360–369. doi:10.1521/
psyc.2009.72.4.360
Barnett, J. H., Scoriels, L., & Munafo, M. R. (2008). Meta-analysis 
of  the  cognitive  effects  of  the  catechol-O-methyltransferase 
gene Val158/108Met polymorphism. Biological Psychiatry, 64, 
137–144. doi:10.1016/j.biopsych.2008.01.005
Berrettini,  W.  H.,  Wileyto,  E.  P.,  Epstein,  L.,  Restine,  S.,   
Hawk, L., Shields, P., et al. (2007). Catechol-O-methyltransferase 
(COMT) gene variants predict response to bupropion therapy 
for  tobacco  dependence.  Biological  Psychiatry,  61,  111–118. 
doi:10.1016/j.biopsych.2006.04.030
Beuten, J., Payne, T. J., Ma, J. Z., & Li, M. D. (2006). Significant 
association  of  catechol-O-methyltransferase  (COMT)  haplo-
types with nicotine dependence in male and female smokers of 
two  ethnic  populations.  Neuropsychopharmacology,  31,  675–
684. doi:10.1038/sj.npp.1300997
Bilder, R. M., Volavka, J., Lachman, H. M., & Grace, A. A. 
(2004). The catechol-O-methyltransferase polymorphism: Re-
lations to the tonic-phasic dopamine hypothesis and neuropsy-
chiatric phenotypes. Neuropsychopharmacology, 29, 1943–1961. 
doi:10.1038/sj.npp.1300542
Breitling,  L.  P.,  Dahmen,  N.,  Illig,  T.,  Rujescu,  D.,  Nitz,  B., 
Raum, E., et al. (2009). Variants in COMT and spontaneous 
smoking cessation: Retrospective cohort analysis of 925 cessa-
tion  events.  Pharmacogenetics  and  Genomics,  19,  657–659. 
doi:10.1097/FPC.0b013e32832fabf3
Brody, A. L., Mandelkern, M. A., Olmstead, R. E., Scheibal, D., 
Hahn, E., Shiraga, S., et al. (2006). Gene variants of brain dopa-
mine pathways and smoking-induced dopamine release in the 
ventral caudate/nucleus accumbens. Archives of General Psychi-
atry, 63, 808–816. doi:10.1001/archpsyc.63.7.808
Chapman, S., & MacKenzie, R. (2010). The global research   
neglect of unassisted smoking cessation: Causes and conse-
quences.  PLoS  Medicine,  7,  e1000216.  doi:10.1371/journal.
pmed.1000216
Chen, J., Lipska, B. K., Halim, N., Ma, Q. D., Matsumoto, M., 
Melhem, S., et al. (2004). Functional analysis of genetic varia-
tion  in  catechol-O-methyltransferase  (COMT):  Effects  on 
mRNA, protein, and enzyme activity in postmortem human 
brain. American Journal of Human Genetics, 75, 807–821. doi:10.
1086/425589
Clarke, H., Flint, J., Attwood, A. S., & Munafo, M. R. (2010). 
Association of the 5-HTTLPR genotype and unipolar depres-
sion: A meta-analysis. Psychological Medicine, 40, 1767–1778. 
doi:10.1017/S0033291710000516
Colhoun, H. M., McKeigue, P. M., & Davey Smith, G. (2003). 
Problems  of  reporting  genetic  associations  with  complex   
outcomes. Lancet, 361, 865–872. doi:10.1016/S0140-6736(03)
12715-8
Colilla, S., Lerman, C., Shields, P. G., Jepson, C., Rukstalis, M., 
Berlin, J., et al. (2005). Association of catechol-O-methyltrans-
ferase with smoking cessation in two independent studies of 
women. Pharmacogenetics and Genomics, 15, 393–398. doi:10.
1097/01213011-200506000-00004
Contin,  M.,  Martinelli,  P.,  Mochi,  M.,  Albani,  F.,  Riva,  R.,   
Scaglione, C., et al. (2004). Dopamine transporter gene poly-
morphism, spect imaging, and levodopa response in patients 
with Parkinson disease. Clinical Neuropharmacology, 27, 111–115. 
doi:10.1097/00002826-200405000-00004
Davey-Smith,  G.,  Lawlor,  D.  A.,  Harbord,  R.,  Timpson,  N.,   
Day, I., & Ebrahim, S. (2007). Clustered environments and ran-
domized  genes:  A  fundamental  distinction  between  conven-
tional  and  genetic  epidemiology.  PLoS  Medicine,  4,  e352. 
doi:10.1371/journal.pmed.0040352
David, S. P., Johnstone, E., Griffiths, S. E., Murphy, M., Yudkin, P., 
Mant, D., et al. (2002). No association between functional cate-
chol O-methyl transferase 1947A>G polymorphism and smok-
ing  initiation,  persistent  smoking  or  smoking  cessation. 
Pharmacogenetics, 12, 265–268. Retrieved from http://journals
.lww.com/jpharmacogenetics/pages/default.aspx
Egger, M., Davey Smith, G., Schneider, M., & Minder, C. (1997). 
Bias in meta-analysis detected by a simple, graphical test. British 
Medical Journal, 315, 629–634. Retrieved from http://www.bmj
.com/
Faul,  F.,  Erdfelder,  E.,  Lang,  A.  G.,  &  Buchner,  A.  (2007). 
G*Power 3: A flexible statistical power analysis program for   
the  social,  behavioral,  and  biomedical  sciences.  Behavior 
Research  Methods,  39,  175–191.  Retrieved  from  http://brm
.psychonomic-journals.org/
Golding, J., Pembrey, M., & Jones, R. (2001). ALSPAC—The 
Avon  Longitudinal  Study  of  Parents  and  Children.  I.  Study 62
COMT Genotype and Smoking Behaviour
methodology. Paediatric and Perinatal Epidemiology, 15, 74–87. 
doi:10.1046/j.1365-3016.2001.00325.x
Guo,  S.,  Chen  da,  F.,  Zhou,  D.  F.,  Sun,  H.  Q.,  Wu,  G.  Y.,   
Haile, C. N., et al. (2007). Association of functional catechol   
O-methyl transferase (COMT) Val108Met polymorphism with 
smoking severity and age of smoking initiation in Chinese male 
smokers. Psychopharmacology (Berlin), 190, 449–456. doi:10.1007/
s00213-006-0628-4
Higgins, J. P., Thompson, S. G., Deeks, J. J., & Altman, D. G. 
(2003).  Measuring  inconsistency  in  meta-analyses.  British 
Medical  Journal,  327,  557–560.  doi:10.1136/bmj.327.7414.
557
Hughes, J. R. (2003). Motivating and helping smokers to stop 
smoking. Journal of General Internal Medicine, 18, 1053–1057. 
doi:10.1111/j.1525-1497.2003.20640.x
Ioannidis, J. P., Ntzani, E. E., Trikalinos, T. A., & Contopoulos-
Ioannidis, D. G. (2001). Replication validity of genetic asso-
ciation  studies.  Nature  Genetics,  29,  306–309.  doi:10.1038/
ng749
Johnstone, E. C., Elliot, K. M., David, S. P., Murphy, M. F.,   
Walton, R. T., & Munafo, M. R. (2007). Association of COMT 
Val108/158Met genotype with smoking cessation in a nicotine 
replacement  therapy  randomized  trial.  Cancer  Epidemiology 
Biomarkers and Prevention, 16, 1065–1069. doi:10.1158/1055-
9965.EPI-06-0936
Jonsson,  E.  G.,  Nothen,  M.  M.,  Grunhage,  F.,  Farde,  L.,   
Nakashima, Y., Propping, P., et al. (1999). Polymorphisms in the 
dopamine D2 receptor gene and their relationships to striatal 
dopamine  receptor  density  of  healthy  volunteers.  Molecular 
Psychiatry, 4, 290–296. doi:10.1038/sj.mp.4000532
Lachman,  H.  M.,  Papolos,  D.  F.,  Saito,  T.,  Yu,  Y.  M.,   
Szumlanski,  C.  L.,  &  Weinshilboum,  R.  M.  (1996).  Human   
catechol-O-methyltransferase  pharmacogenetics:  Description 
of  a  functional  polymorphism  and  its  potential  application   
to  neuropsychiatric  disorders.  Pharmacogenetics,  6,  243–250. 
doi:10.1097/00008571-199606000-00007
Liu, J. Z., Tozzi, F., Waterworth, D. M., Pillai, S. G., Muglia, P., 
Middleton, L., et al. (2010). Meta-analysis and imputation re-
fines the association of 15q25 with smoking quantity. Nature 
Genetics, 42, 436–440. doi:10.1038/ng.572
Lu,  Y.,  Tong,  S.,  &  Oldenburg,  B.  (2001).  Determinants  of 
smoking  and  cessation  during  and  after  pregnancy.  Health 
Promotion  International,  16,  355–365.  doi:10.1093/heapro/
16.4.355
McKinney,  E.  F.,  Walton,  R.  T.,  Yudkin,  P.,  Fuller,  A.,   
Haldar, N. A., Mant, D., et al. (2000). Association between 
polymorphisms in dopamine metabolic enzymes and tobacco 
consumption  in  smokers.  Pharmacogenetics,  10,  483–491. 
Retrieved from http://journals.lww.com/jpharmacogenetics/pages 
/default.aspx
Munafo, M. R. (2009). Reliability and replicability of genetic as-
sociation  studies.  Addiction,  104,  1439–1440.  doi:10.1111/
j.1360-0443.2009.02662.x
Munafo,  M.  R.,  Clark,  T.,  Johnstone,  E.,  Murphy,  M.,  &   
Walton,  R.  (2004).  The  genetic  basis  for  smoking  behavior:   
A  systematic  review  and  meta-analysis.  Nicotine  &  Tobacco 
Research, 6, 583–597. doi:10.1080/14622200410001734030
Munafo, M. R., & Flint, J. (2004). Meta-analysis of genetic as-
sociation studies. Trends in Genetics, 20, 439–444. doi:10.1016/
j.tig.2004.06.014
Munafo, M. R., Heron, J., & Araya, R. (2008). Smoking patterns 
during pregnancy and postnatal period and depressive symp-
toms. Nicotine & Tobacco Research, 10, 1609–1620. doi:10.1080/
14622200802412895
Munafo, M. R., Johnstone, E. C., Guo, B., Murphy, M. F., & 
Aveyard, P. (2008). Association of COMT Val108/158Met gen-
otype with smoking cessation. Pharmacogenetics and Genomics, 
18, 121–128. doi:10.1097/FPC.0b013e3282f44daa
Nedic, G., Nikolac, M., Borovecki, F., Hajnsek, S., Muck-Seler, D., 
& Pivac, N. (2010). Association study of a functional catechol-
o-methyltransferase  polymorphism  and  smoking  in  healthy 
Caucasian subjects. Neuroscience Letters, 473, 216–219. doi:10.
1016/j.neulet.2010.02.050
Omidvar,  M.,  Stolk,  L.,  Uitterlinden,  A.  G.,  Hofman,  A.,   
Van Duijn, C. M., & Tiemeier, H. (2009). The effect of catechol-
O-methyltransferase  Met/Val  functional  polymorphism  on 
smoking cessation: Retrospective and prospective analyses in a 
cohort  study.  Pharmacogenetics  and  Genomics,  19,  45–51. 
doi:10.1097/FPC.0b013e328317f3f8
Saccone,  S.  F.,  Pergadia,  M.  L.,  Loukola,  A.,  Broms,  U.,   
Montgomery, G. W., Wang, J. C., et al. (2007). Genetic linkage 
to chromosome 22q12 for a heavy-smoking quantitative trait in 
two independent samples. American Journal of Human Genetics, 
80, 856–866. doi:10.1086/513703
Shield, A. J., Thomae, B. A., Eckloff, B. W., Wieben, E. D., & 
Weinshilboum, R. M. (2004). Human catechol O-methyltrans-
ferase  genetic  variation:  Gene  resequencing  and  functional 
characterization of variant allozymes. Molecular Psychiatry, 9, 
151–160. doi:10.1038/sj.mp.4001386
Shiels, M. S., Huang, H. Y., Hoffman, S. C., Shugart, Y. Y., 
Bolton, J. H., Platz, E. A., et al. (2008). A community-based 
study of cigarette smoking behavior in relation to variation in 
three  genes  involved  in  dopamine  metabolism:  Catechol-O-
methyltransferase  (COMT),  dopamine  beta-hydroxylase 
(DBH) and monoamine oxidase-A (MAO-A). Preventive Medi-
cine, 47, 116–122. doi:10.1016/j.ypmed.2008.03.013
Szreter, S. R. S. (1984). The genesis of the Registrar-General’s 
social classification of occupations. British Journal of Sociology, 
35, 522–546. doi:10.2307/590433
Thorgeirsson, T. E., Gudbjartsson, D. F., Surakka, I., Vink, J. M., 
Amin,  N.,  Geller,  F.,  et  al.  (2010).  Sequence  variants   
at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. 
Nature Genetics, 42, 448–453. doi:10.1038/ng.573
Tobacco-and-Genetics-Consortium.  (2010).  Genome-wide 
meta-analyses identify multiple loci associated with smoking 
behavior. Nature Genetics, 42, 441–447. doi:10.1038/ng.57163
Nicotine & Tobacco Research, Volume 13, Number 2 (February 2011) 
Ton, T. G., Rossing, M. A., Bowen, D. J., Srinouanprachan, S., 
Wicklund, K., & Farin, F. M. (2007). Genetic polymorphisms in 
dopamine-related  genes  and  smoking  cessation  in  women:   
A prospective cohort study. Behavioral and Brain Functions, 3, 
22. doi:10.1186/1744-9081-3-22
Twigg, L., Moon, G., Szatkowski, L., & Iggulden, P. (2009). 
Smoking cessation in England: Intentionality, anticipated ease 
of quitting and advice provision. Social Science and Medicine, 68, 
610–619. doi:10.1016/j.socscimed.2008.11.032
Weinshilboum, R. M., Otterness, D. M., & Szumlanski, C. L. 
(1999). Methylation pharmacogenetics: Catechol O-methyltrans-
ferase, thiopurine methyltransferase, and histamine N-methyl-
transferase. Annual Review of Pharmacology and Toxicology, 39, 
19–52. doi:10.1146/annurev.pharmtox.39.1.19